ReviewAging and disease2025
Spinal Cord Injury and Ageing: The Role of Chronic Neuroinflammation.
Review in Aging and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Research Progress on Biomaterial Scaffolds Carrying Stem Cells for Inflammation Regulation After Spinal Cord Injury.Stem cell reviews and reports · 2026Review
- Construction of a Computationally Inferred Single-Cell miRNA Activity Atlas and Analysis of Regulatory Networks in Spinal Cord Injury.Journal of molecular neuroscience : MN · 2026Article
- Exosome-derived ncRNAs and proteins: inflammation regulatory mechanisms and biomarker potential in spinal cord injury.Frontiers in molecular biosciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As the global population ages, there is an increasing prevalence of spinal cord injury (SCI) among elderly individuals, accompanied by significant challenges in treatment and recovery. Age-related conditions, such as osteoporosis, muscle atrophy, and impaired balance, predispose older adults to falls and traumatic injuries, leading to worse neurological outcomes compared to younger patients. SCI pathophysiology consists of two phases: the initial mechanical injury and the secondary injury that involves a cascade of pathological events, including ischemia, apoptosis, and neuronal cell death. Chronic neuroinflammation has emerged as a central factor in driving long-term damage after SCI, particularly in older people, where immune senescence and a decreased ability to resolve inflammation contribute to persistent, unresolved inflammation. This prolonged inflammatory state further impedes neural regeneration and functional recovery. Aged animal models have revealed that chronic neuroinflammation is exacerbated by sustained activation of microglia and astrocytes, the infiltration of peripheral immune cells, and the secretion of pro-inflammatory cytokines, creating a pro-inflammatory microenvironment that hinders repair. Furthermore, ageing-related factors such as immunosenescence, autophagy dysfunction, and mitochondrial abnormalities exacerbate inflammation, establishing a vicious injury cycle. Despite promising studies targeting inflammation in young SCI models, there is a critical need for age-specific therapeutic approaches for elderly SCI patients. This review explores the mechanisms of chronic inflammation in aged SCI, examines key cellular mediators, and discusses potential therapeutic strategies, including pharmacological treatments, gene therapy, exosome-based interventions, and rehabilitation. Focusing on age-related differences in inflammation and healing, this work aims to provide a foundation for precision medicine tailored to the ageing population with SCI, ultimately improving clinical outcomes and quality of life for elderly patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.